API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of agreement, Regeneron is responsible for the clinical development and will assume all costs associated with the study, other than expenses related to the manufacturing and supply of nirogacestat and certain expenses related to intellectual property rights.
Lead Product(s): Nirogacestat Hydrobromide,REGN5458
Therapeutic Area: Oncology Product Name: PF-03084014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2022
Details:
New data for REGN5458 (BCMAxCD3 bispecific antibody) in patients with heavily pre-treated multiple myeloma to be highlighted. First data evaluating combination therapy approach with pozelimab (C5 antibody) and Alnylam's cemdisiran (siRNA C5 inhibitor) in healthy volunteers.
Lead Product(s): REGN5458
Therapeutic Area: Oncology Product Name: REGN5458
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
REGN5458 continues to show early, deep and durable anti-tumor responses in patients with relapsed and refractory multiple myeloma across all dose levels.
Lead Product(s): REGN5458
Therapeutic Area: Oncology Product Name: REGN5458
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020